Brokerages Anticipate Leap Therapeutics Inc (NASDAQ:LPTX) to Post -$0.32 Earnings Per Share

Brokerages forecast that Leap Therapeutics Inc (NASDAQ:LPTX) will announce earnings of ($0.32) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Leap Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.35) and the highest estimate coming in at ($0.28). Leap Therapeutics reported earnings per share of ($0.50) in the same quarter last year, which suggests a positive year over year growth rate of 36%. The firm is scheduled to announce its next quarterly earnings results on Monday, April 6th.

According to Zacks, analysts expect that Leap Therapeutics will report full year earnings of ($1.43) per share for the current financial year, with EPS estimates ranging from ($1.50) to ($1.39). For the next year, analysts forecast that the firm will post earnings of ($1.09) per share, with EPS estimates ranging from ($1.71) to ($0.69). Zacks’ EPS averages are an average based on a survey of research analysts that cover Leap Therapeutics.

Leap Therapeutics (NASDAQ:LPTX) last announced its earnings results on Thursday, November 14th. The company reported ($0.33) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.33).

A number of brokerages recently weighed in on LPTX. HC Wainwright reissued a “buy” rating and set a $3.25 price objective on shares of Leap Therapeutics in a report on Friday, November 15th. Zacks Investment Research downgraded Leap Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 15th. Finally, Raymond James lowered Leap Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Friday, November 15th.

Institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC raised its holdings in Leap Therapeutics by 63.3% in the 1st quarter. FMR LLC now owns 1,563,124 shares of the company’s stock worth $2,923,000 after purchasing an additional 606,000 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Leap Therapeutics by 183.4% during the 2nd quarter. Vanguard Group Inc. now owns 555,195 shares of the company’s stock valued at $994,000 after buying an additional 359,320 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Leap Therapeutics by 40.0% during the 2nd quarter. BlackRock Inc. now owns 34,233 shares of the company’s stock valued at $61,000 after buying an additional 9,782 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Leap Therapeutics in the 3rd quarter worth about $28,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Leap Therapeutics in the 2nd quarter worth about $42,000. 15.61% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ LPTX opened at $0.82 on Friday. The stock’s 50-day simple moving average is $0.96 and its two-hundred day simple moving average is $1.44. Leap Therapeutics has a twelve month low of $0.57 and a twelve month high of $3.55. The company has a quick ratio of 1.39, a current ratio of 1.39 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $19.31 million, a price-to-earnings ratio of -0.33 and a beta of 2.25.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.

Recommended Story: What is net income?

Get a free copy of the Zacks research report on Leap Therapeutics (LPTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit